WGS:NSD-GeneDx Holdings Corp. (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 98.47

Change

0.00 (0.00)%

Market Cap

USD 2.75B

Volume

0.92M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company is headquartered in Stamford, Connecticut.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-16 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

N/A

USD 35.55B
NTRA Natera Inc

N/A

USD 21.03B
ICLR ICON PLC

N/A

USD 16.66B
ILMN Illumina Inc

N/A

USD 14.06B
MEDP Medpace Holdings Inc

N/A

USD 9.97B
EXAS EXACT Sciences Corporation

N/A

USD 9.13B
GH Guardant Health Inc

N/A

USD 4.85B
RDNT RadNet Inc

N/A

USD 4.54B
SHC Sotera Health Co

N/A

USD 3.23B
VCYT Veracyte Inc

N/A

USD 3.18B

ETFs Containing WGS

XHS SPDR® S&P Health Care Se.. 2.44 % 0.35 %

N/A

USD 0.08B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 28.12% 86% B+ 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.12% 86% B+ 93% A
Trailing 12 Months  
Capital Gain 719.90% 100% F 100% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 719.90% 100% F 100% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 4,733.73% 98% N/A 99% N/A
Dividend Return 4,733.73% 98% N/A 99% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 21,372.67% 4% F 1% F
Risk Adjusted Return 22.15% 75% C 55% F
Market Capitalization 2.75B 76% C+ 83% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector